Article Sidebar

PDF
Date Published: 05/01/2022
Abstract Views: 430
Views PDF: 189
DOI: https://doi.org/10.51298/vmj.v508i1.1550
Issue
Vol. 508 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Trang, N. ., & Hồng Khoa, P. . (2022). TREATMENT OUTCOME IN PATIENTS WITH STAGE II-IIIA BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY IN THANH HOA ONCOLOGY HOSPITAL. Vietnam Medical Journal, 508(1). https://doi.org/10.51298/vmj.v508i1.1550

TREATMENT OUTCOME IN PATIENTS WITH STAGE II-IIIA BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY IN THANH HOA ONCOLOGY HOSPITAL

Nguyễn Thị Trang1,, Phạm Hồng Khoa2
1 Hanoi Medical University
2 K Hospital

Main Article Content

Abstract

Objectives: To evaluate survival outcomes and some related factors in patients with stage II-IIIA breast cancer treated with 4AC-4D (A: doxorubicine, C: cyclophosphamide and D: docetaxel) adjuvant chemotherapy. Subjects and methods: Including 74 patients diagnosed with breast cancer stage II-IIIA who underwent radical surgery, adjuvant chemotherapy at Thanh Hoa Oncology Hospital, from February 2014 to April 2021. Results: The mean age of the study group was 46.62 ± 7.05 years. All 74 patients completed 8 cycles of 4AC-4D chemotherapy, none of which stopped treatment. The mean study time was 69 months, the 5-year disease-free survival rate was 53.6% with the mean disease-free survival time was 63.95 ± 2.34 months, the overall survival rate after 5 years was 89.2% with a mean overall survival time of 78.70 ± 1.60months. Factors affecting treatment include stage, hormonal receptor status and HER2 status. Conclusion: Applying the 4AC-4D regimen on patients with stage II-IIIA adjuvant breast cancer at Thanh Hoa Oncology Hospital has high efficiency.

Article Details

Keywords

breast cancer stage II-IIIA, 4AC-4D, adjuvant

References

1. Paridaens R., Biganzoli L., Bruning P., et al. (2000). Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol, 18(4), 724–733.
2. Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, Falkson HC. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer. 1985;56(2):219-224. doi:10.1002/1097-0142(19850715)56:2<219::aid-cncr2820560202>3.0.co;2-q
3. Tranum BL, McDonald B, Thigpen T, et al. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer. 1982;49(5):835-839. doi:10.1002/1097-0142(19820301)49:5<835::aid-cncr2820490502>3.0.co;2-z
4. Taylor SG, Gelber RD. Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer. Cancer Treat Rep. 1982; 66(7): 1594-1595.
5. Trần Văn Thuấn. Đánh giá kết quả điều trị bổ trợ hóa chất phác đồ Adriamycin-Cyclophosphamid kết hợp với điều trị nội tiết trên bệnh nhân ung thư vú giai đoạn II-III. Luận văn tiến sỹ; 2005.
6. Lê Thị Sương. Đánh giá kết quả điều trị bổ trợ ung thư vú giai đoạn II-IIIA bằng phác đồ 4AC-4D Luận văn thạc sỹ; 2017.
7. Tạ Văn Tờ. Nghiên cứu hình thái học, hóa mô miễn dịch và giá trị tiên lượng của chúng trong ung thư biểu mô tuyến vú. Luận văn Tiến sỹ Y học; 2004.
8. Lý Thị Thu Hiền. Đánh giá hiệu quả điều trị bổ trợ phác đồ 4AC- 4D trên bệnh nhân ung thư vú có bộ ba âm , Luận văn thạc sỹ; 2018.
9. Đỗ Thị Kim Anh. Đánh giá kết quả hóa chất bổ trợ phác đồ 4AC-4P trên bệnh nhân ung thư vú gia đoạn II-III tại bệnh viện K luận văn thạc sỹ; 2008.